CU Anschutz Hematology Shines at ASH 2024! University of Colorado Anschutz Medical Campus Hematology made a huge impact at the 66th Annual American Society of Hematology Conference with a record-setting 47 abstracts. Their groundbreaking research and innovative advancements underscore their commitment to improving patient care. Congratulations to the entire team for their dedication and hard work! Read more in our newsroom: https://lnkd.in/gEeTeP97
CU Innovations
Higher Education
Aurora, CO 1,620 followers
Biomedical technology licensing and commercialization | Funding Resources | Healthcare Industry Partnerships
About us
#CUInnovations brings together industry partners, entrepreneurs, and investors to help CU Researchers solve important problems and improve the quality of life worldwide. With expertise in patents, copyrights, and licensing, we help translate discovery into impact through transparent, flexible, best practice intellectual property management services. We connect researchers at CU Anschutz Medical Campus with a variety of commercialization programs in the university and the community.
- Website
-
https://www.cuanschutz.edu/cu-innovations
External link for CU Innovations
- Industry
- Higher Education
- Company size
- 11-50 employees
- Headquarters
- Aurora, CO
- Type
- Educational
- Specialties
- Licensing, IP Law, Patents, Copyrights, Venture, Startups, Higher Education, Technology Transfer, Entrepreneurship, Commercialization, Healthcare, Medicine, Drug Development, Funding Opportunities, and BioTech
Locations
-
Primary
Get directions
13001 E. 17th Place
Suite W5130
Aurora, CO 80045, US
Employees at CU Innovations
-
Mike McGarry
Sr. Director Of Business Development & Licensing at CU Innovations
-
Doreen Molk
Senior Licensing Manager at University of Colorado Anschutz Medical Campus
-
Thomas Utley
Innovation Manager | Alliances | Licensing | Healthcare IT | Pharmaceutical
-
Kimberly Taylor
Patent Administrator/Manager - CU Innovations
Updates
-
Congratulations to Steven VanNurden, Associate Vice Chancellor for Biotechnology at University of Colorado Anschutz Medical Campus, on his well-deserved retirement. From Mayo Clinic to Colorado, his 35-year-long career has always been about patient care. Thank you, Steve, for your incredible contributions! #cuinnovations #cuanschutz
Fitzsimons Innovation Community President and CEO Steven VanNurden Announces Retirement “Steve VanNurden’s visionary leadership has been instrumental in transforming Fitzsimons Innovation Community into a thriving world-class hub for life sciences innovation. Over the past 12 years, he has not only built an ecosystem where groundbreaking research and collaboration flourish but has also laid a foundation for the future of biotech and health sciences here in Colorado.” David Perez, Fitzsimons Innovation Community Board Member Read the announcement: https://lnkd.in/eBSM98Yt
-
-
We are excited to share that University of Colorado Anschutz Medical Campus researchers have been awarded up to $46 million for Advanced Research Projects Agency for Health (ARPA-H)'s THEA program, which aims to drive groundbreaking research in curing total blindness through human eye transplantation. CU Innovations is thrilled to be part of this transformative journey and learn more about how this funding could change the future of vision restoration. #cuinnovations #cuanschutz
BREAKING: We are thrilled to announce that a research team led by #CUAnschutz will receive up to $46 million in federal funding from the Advanced Research Projects Agency for Health (ARPA-H) to advance pioneering research aimed at curing total blindness through human eye transplantation. Learn more about how this funding could transform the future of sight restoration for the millions of Americans facing blindness and vision loss: https://bit.ly/4i8MeHA
-
We’re filled with gratitude for our incredible partners, whose dedication drives innovation and transforms lives. Thank you for inspiring us every day—together, we’re making a meaningful impact on the future of healthcare. #cuinnovations #cuanschutz
-
-
Big news from our partners at OncoVerity! They successfully obtained extended Series A funding to further develop cusatuzumab, a groundbreaking therapy for AML, with the Phase 2 trial already underway. Stay tuned for interim results in 2025 & visit our newsroom to learn more: https://lnkd.in/guPTskW5 #cuinnovations #cuanschutz
Excited to share that OncoVerity has secured additional funding to advance our mission of transforming hope into reality for cancer patients. Our Phase 2 trial evaluating cusatuzumab is officially underway and has enrolled its first patients! https://lnkd.in/gBj3K3yC
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML
businesswire.com
-
🎉 Huge congratulations to Steven VanNurden on receiving the Lifetime Achievement Award at Colorado BioScience Association’s 21st Annual Awards Celebration presented by AGC Biologics! Steve has been a driving force in advancing life sciences in Colorado, bridging academic innovation with real-world solutions that save lives. His dedication to building a thriving ecosystem for innovation has left a lasting mark on the industry and the community. 🌟 #cuinnovations #cuanschutz
At tonight’s 21st Annual Awards Celebration Presented by AGC Biologics, CBSA honored Steven VanNurden, Associate Vice Chancellor of Biotechnology at the University of Colorado Anschutz Medical Campus and President & CEO of Fitzsimons Innovation Community, with the Lifetime Achievement Award for his pioneering contributions to Colorado’s life sciences landscape. His career has been marked by his leadership in transforming academic discoveries into life-saving products and his impact in expanding innovation infrastructure for Colorado’s life sciences companies. Our community celebrates Steve for his vision, passion, and commitment to patients! #COBioScience #StrongerTogether #AllIn
-
-
Congratulations to CU Healthcare Innovation Fund portfolio company, Jupiter Bioventures! Led by visionary co-founders, Nathaniel David & Norman Sharpless, Jupiter recently secured $70M in financing to fuel their mission of building therapeutics companies dedicated to transforming patient care. Excited for what’s to come! Read more in our newsroom: https://lnkd.in/guPTskW5 #cuinnovations #cuanschutz
We’re excited to officially launch Jupiter Bioventures, a pioneering biotechnology venture foundry building bold, science-driven therapeutics companies. Co-Founders Nathaniel David, PhD, and Norman Sharpless, MD, bring decades of industry experience to drive a scalable foundry model, advancing #biotech innovation in #cancer and other areas in which insights from cancer biology provide insight. With $70 million raised from returning investors Mission BioCapital and Mayo Clinic alongside #lifescience investors Alexandria Venture Investments, Bioventure Partners, Cedars-Sinai Intellectual Property Company, CU Healthcare Innovation Fund, Eric Ball, Eshelman Ventures, LLC, Fox Ventures, The Brent and Julie Callinicos Trust and Vault Fund, Jupiter will found, launch, and operate multiple therapeutics companies. https://lnkd.in/eaUJsaE8 Stay tuned as we pursue breakthrough science to deliver #innovation in life sciences.
-
-
Now at Fitzsimons Innovation Community, RefinedScience’s growth highlights the power of collaboration between academia and industry. With a focus on drug development and discovery through comprehensive data analysis, RefinedScience is shaping the future of healthcare. Visit our newsroom to learn more: https://lnkd.in/guPTskW5 #cuinnovations #cuanschutz
“We were born out of this University, and we continue to have extremely strong ties to it. We’ve obviously evolved and now have our own identity, too, but we’ve learned that bringing the best of academia and the best of industry together can create the best company, so we never want to lose that connection.” Erik Johnson, CEO, RefinedScience Read the announcement: https://lnkd.in/ekG8tk7H Read our recent blog post: https://lnkd.in/ehPkrX3M
-
-
Boost your research impact with clear communication! 🌟 Join the Clinical Research Recruitment team on Wednesday 11/20 from 12–1 for a workshop led by Associate Professor, Dana Abbey. Learn how plain language can improve health literacy, build trust, and reach diverse populations. Register now: https://lnkd.in/gPiXbRaP #cuinnovations #cuanschutz
Welcome! You are invited to join a meeting: Clearer Communication, Healthier Outcomes: The Role of Plain Language in Research. After registering, you will receive a confirmation email about joining the meeting.
ucdenver.zoom.us
-
Our executive director, Kimberly Muller, will be one of six distinguished judges at this exciting #startup pitch competition in Houston TX. If you are in the area, don’t miss the opportunity to connect with these startups & industry experts: #cuinnovations #cuanschutz
We are thrilled to introduce our distinguished judges for the 2024 Fire Pitch Competition! Allison Rhines – Head of JLABS, Houston Andrew Truscott – Global Health Technology Lead, Accenture Angela Shippy MD – Sr. Physician Executive, Amazon Web Services (AWS) Kimberly Muller – Executive Director, CU Innovations, University of Colorado Anschutz Medical Campus Myra Davis – Chief Innovation and Information Officer, Texas Children's Hospital Winjie Tang Miao – SEVP and Chief Operating Officer, Texas Health Resources Join us as the top startups from the 2024 Ignite accelerator take the stage to pitch in front of investors, partners, and industry leaders—competing for prestigious awards and prizes that will help propel their businesses to the next level. 🎟️ Don’t miss out! Register now to witness innovation in action: https://lnkd.in/eBnETXe6 #FirePitchCompetition #Entrepreneurship #HealthcareInnovation #Ignite #HoustonEvents #Innovation #Startups
-